🔴 Moderna is trading 4.2% down with no verified company-specific catalyst

Moderna is trading 4.2% lower at $194.67, with no verified company-specific announcement identified to explain the October 6 decline.

• The October 5 gain also lacked a clearly verified company-specific catalyst; Nasdaq-100 inclusion is recent context, not a confirmed explanation for this move.
• Biotech ETF XBI is down 2.50%, which may add pressure, but available evidence does not establish that sector weakness directly explains Moderna’s drop.
• The broader market is higher, so no clear global-market cause is apparent.